Sionna Therapeutics, Inc. (SION)
Automate Your Wheel Strategy on SION
With Tiblio's Option Bot, you can configure your own wheel strategy including SION - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SION
- Rev/Share 0.0
- Book/Share 7.6258
- PB 2.7525
- Debt/Equity 0.0275
- CurrentRatio 35.3306
- ROIC -0.2054
- MktCap 926494906.0
- FreeCF/Share -1.2802
- PFCF -16.4039
- PE -15.7085
- Debt/Assets 0.0262
- DivYield 0
- ROE -0.6272
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SION | Guggenheim | -- | Buy | -- | $45 | March 4, 2025 |
| Initiation | SION | Stifel | -- | Buy | -- | $32 | March 4, 2025 |
| Initiation | SION | TD Cowen | -- | Buy | -- | -- | March 4, 2025 |
News
Sionna Therapeutics Reports Second Quarter 2025 Financial Results
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Announced positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally well tolerated and exceeded pharmacokinetic targets Initiation of Phase 2a proof-of-concept trial of SION-719 as an add-on to standard of care in cystic fibrosis patients is on track for the second half of 2025 with topline data expected in mid-2026 Advancement of Phase 1 healthy volunteer trial of SION-451 in two proprietary dual combinations is on track for the second half of 2025 with topline data expected in mid-2026 Maintained strong cash position with approximately $337.3 million in cash and cash equivalents, expected to …
Read More
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data featured in oral presentation and poster session at 48 th European Cystic Fibrosis Conference
Read More
Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Healthcare Conference in Miami, Florida on Wednesday, June 11th 2025 at 8:00 a.m.
Read More
Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that preclinical data assessing combinations of Sionna's nucleotide-binding domain 1 (NBD1) stabilizers, SION-451 and SION-719, with complementary Sionna CFTR modulators, galicaftor (SION-2222) and SION-109, will be featured in an oral presentation at the European Cystic Fibrosis Society's (ECFS) 48th European Cystic Fibrosis Conference, being held June 4-7, 2025 in Milan, Italy.
Read More
Sionna Therapeutics Reports First Quarter 2025 Financial Results
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1 topline data anticipated this quarter On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026 Strong cash position following completed upsized IPO, with approximately $354.7 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current …
Read More
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025
Read More
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 45th Annual TD Cowen Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET.
Read More
About Sionna Therapeutics, Inc. (SION)
- IPO Date 2025-02-07
- Website https://www.sionnatx.com
- Industry Biotechnology
- CEO Michael Cloonan
- Employees 41